Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on October 27, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks. Group 1: Buyback Details - China Feihe (06186) repurchased 5.886 million shares for a total of 24.0721 million yuan, representing 0.152% of its total share capital with a year-to-date total of 13.771 million shares repurchased [1][2] - Guosheng Tang (02273) repurchased 244,400 shares for 7.1899 million yuan, with a year-to-date total of 5.5026 million shares, accounting for 2.322% of its total share capital [2] - Mengniu Dairy (02319) repurchased 400,000 shares for 5.7710 million yuan, with a year-to-date total of 21.716 million shares, representing 0.555% of its total share capital [2] Group 2: Other Notable Buybacks - Lianlian Digital (02598) repurchased 711,000 shares for 5.7458 million yuan, with a year-to-date total of 2.5925 million shares, accounting for 0.620% of its total share capital [2] - Zhongxu Future (09890) repurchased 345,200 shares for 5.0690 million yuan, with a year-to-date total of 647,400 shares, representing 1.210% of its total share capital [2] - Kangchen Pharmaceutical (01681) repurchased 100,000 shares for 1.5400 million yuan, with a year-to-date total of 740,600 shares, accounting for 8.700% of its total share capital [2][3]

Core Viewpoint - Tianan Health (00383) announced a share buyback of 75,000 shares at a total cost of HKD 72,800, with a buyback price of HKD 0.97 per share [1] Summary by Category - **Company Actions** - The company executed a buyback of 75,000 shares on October 27, 2025 [1] - The total expenditure for the buyback was HKD 72,800 [1] - The price per share for the buyback was set at HKD 0.97 [1]

Core Viewpoint - Tianan Health (00383) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Category Company Actions - The company plans to repurchase 75,000 shares at a total cost of HKD 72.8 million, with each share priced at HKD 0.97 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 天安卓健有限公司 呈交日期： 2025年10月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | | 是 | | | | | 證券代號 (如上市) | 00383 | 說明 | | | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 事件 | | 已發行股份（不包括庫 ...

Core Viewpoint - Tianan Health (00383) announced the resignation of its auditor, Lixin Dehao Certified Public Accountants, effective from October 24, 2025, and appointed Deloitte Touche Tohmatsu as the new auditor to fill the vacancy until the next annual general meeting [1] Group 1 - Lixin Dehao Certified Public Accountants has resigned as the company's auditor [1] - Deloitte Touche Tohmatsu has been appointed as the new auditor effective from October 24, 2025 [1] - The appointment of Deloitte is to fill the temporary vacancy left by the resignation of Lixin Dehao [1]

Core Points - Tianan Health (00383) announced the resignation of its auditor, Lixin Dehao Accounting Firm, effective from October 24, 2025 [1] - The board, upon the recommendation of the company's audit committee, has appointed Deloitte Touche Tohmatsu as the new auditor, effective from October 24, 2025, to fill the vacancy left by Lixin Dehao [1]

Group 1 - The company Tianan Health (00383.HK) announced the resignation of its auditor, BDO Limited, effective from October 24, 2025 [1] - The board, upon the recommendation of the audit committee, has appointed Deloitte Touche Tohmatsu as the new auditor, effective from October 24, 2025, to fill the vacancy left by BDO's resignation [1] - The new auditor will serve until the conclusion of the company's next annual general meeting [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） MEDICARE 更換核數師 本公佈乃天安卓健有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯 合交易所有限公司證券上市規則第13.51(4)條而作出。 本公司董事會（「董事會」）謹此宣佈，香港立信德豪會計師事務所有限公司（「立信德 豪」）已辭任本公司核數師，自二零二五年十月二十四日起生效。董事會經本公司審 核委員會（「審核委員會」）推薦，已委任德勤 • 關黃陳方會計師行（「德勤」）為本公司 新任核數師，自二零二五年十月二十四日起生效，以填補立信德豪辭任後的臨時空 缺，並任職直至本公司下屆股東週年大會結束為止。 是次更換本公司核數師乃由董事會經審核委員會推薦而決定，旨在使本公司與其最 終控股公司及中間控股公司（現均採用德勤作為其核數師）的審核安排保持一致，從 而提升審核服務之效率，此舉符合本公司及本公司股東（「股東」）整體之最佳利益。 立信德豪已於其辭任函中 ...

Core Insights - The global equipment manufacturing industry is focusing on Shandong Heavy Industry in Qingdao, China, as it hosts the global partner conference with nearly 2,500 partners from 140 countries, showcasing around 300 products and covering an exhibition area of 30,000 square meters [1] - Shandong Heavy Industry reported impressive financial results for the first nine months of 2025, achieving nearly 440 billion yuan in revenue, a year-on-year increase of over 9%, with overseas business accounting for 60% of total revenue, highlighting the company's deepening globalization strategy [1] Globalization Strategy - Shandong Heavy Industry has moved beyond traditional trade to establish a new model of diversified business collaboration in international markets, with 30% of overseas revenue coming from European and American industries and another 30% from localized manufacturing and sales of domestic products [3] - The company has demonstrated strong performance across its subsidiaries, with China National Heavy Duty Truck's export sales reaching 111,000 units, a 24.5% increase, and Weichai Group's engine exports growing by 30% [5][5] Localization and Innovation - The company emphasizes a "deep cultivation of international markets" strategy, focusing on local teams, management, manufacturing, and R&D to address the complexities of the global environment [5] - Weichai's internationalization index has reached 40.93%, with all overseas acquisitions being profitable, driven by a strategy of synergy, localization, and unified goals [7] Technological Advancements - Shandong Heavy Industry invests heavily in R&D, maintaining a research intensity of 4.2%, with an expected investment of 13.6 billion yuan in 2024, leading to significant advancements in engine technology and vehicle design [9] - The company has introduced AI-powered machinery and customized products for specific markets, enhancing its global competitiveness [9] Collaborative Ecosystem - The "We Are One" philosophy fosters a unique collaborative innovation ecosystem, enabling rapid responses to customer needs through supply chain cooperation and shared resources among subsidiaries [10] - This collaborative model provides Shandong Heavy Industry with a competitive edge over Western companies, allowing for faster technological responses [10] Redefining Globalization - Shandong Heavy Industry's globalization practices are redefining the paradigm of Chinese equipment manufacturing, focusing on systemic outputs of technology, management, brand, and culture, rather than just product movement [12] - The company's approach, centered on deep localization, technological innovation, and cooperative win-win strategies, opens new growth avenues and offers significant insights for the high-quality development of Chinese manufacturing [12]

Core Insights - The article presents a ranking of 33 Hong Kong-listed medical service companies based on their stock price performance as of September 30, 2025, highlighting significant price increases and declines among these companies [1][2]. Group 1: Top Performers - The top performer is Brainstorm Cell Therapeutics (脑动极光-B) with a stock price of HKD 8.58, reflecting a remarkable increase of 166.46% [1]. - MediWound (麦迪卫康) ranks second with a stock price of HKD 1.23, showing a growth of 136.54% [1]. - Yonghe Medical (雍禾医疗) comes in third with a stock price of HKD 2.05, marking a rise of 127.78% [1]. Group 2: Notable Declines - The company with the largest decline is Yimeng Group (云康集团), with a stock price of HKD 1.28, experiencing a drop of 86.15% [1]. - Meizhong Jiahe (美中嘉和) follows with a stock price of HKD 3.20, down by 70.91% [1]. - Another significant decline is seen in Yimeng Sunshine (一昧阳光), which has a stock price of HKD 17.00, down by 76.06% [1]. Group 3: Market Capitalization - Fosun Pharma (复星医药) has the highest market capitalization at HKD 680.48 billion, with a stock price of HKD 25.78 [2]. - Far East Horizon (远东宏信) ranks second with a market cap of HKD 328.32 billion and a stock price of HKD 6.87 [2]. - Global Medical (环球医疗) holds a market cap of HKD 114.82 billion, with a stock price of HKD 6.07 [2].